Literature DB >> 10411650

Genomic origin and transcriptional regulation of two variants of cGMP-binding cGMP-specific phosphodiesterases.

J Kotera1, K Fujishige, Y Imai, E Kawai, H Michibata, H Akatsuka, N Yanaka, K Omori.   

Abstract

We have reported alternative splice variants of cGMP-binding cGMP-specific phosphodiesterases (PDE5A), i.e. rat PDE5A2, human PDE5A1, canine PDE5A1 and PDE5A2, which possess distinct N-terminal sequences. In this study, the DNA sequences corresponding to the unique N-terminal portions of PDE5A1 and PDE5A2 were shown to be tandemly located upstream of exons encoding the common region of PDE5A in both human and rat PDE5A genes. The presence of human PDE5A2 and rat PDE5A1 transcripts in lung was confirmed by reverse transcriptase-PCR. These results indicated that two variant forms of PDE5A exist in humans, canines and rats. We examined the tissue distribution of the two variants of human PDE5A in adult and fetal humans. The patterns of expression of the two alternatively spliced transcripts of human PDE5A in human tissues differed. Many putative regulatory elements including cAMP response elements were observed in the 5'-untranslated region and intron of the PDE5A gene. The levels of the PDE5A transcripts, especially the PDE5A2 transcripts, were increased by a cAMP analogue in cultured rat vascular smooth muscle cells, indicating that the PDE5A2 is an inducible variant of PDE5A in rats.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10411650     DOI: 10.1046/j.1432-1327.1999.00450.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  13 in total

Review 1.  cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action.

Authors:  Sharron H Francis; Jennifer L Busch; Jackie D Corbin; David Sibley
Journal:  Pharmacol Rev       Date:  2010-09       Impact factor: 25.468

2.  Evidence for expression and function of phosphodiesterase type 5 (PDE-V) in rat resistance arteries.

Authors:  L J Sampson; J M Hinton; C J Garland
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

Review 3.  Clinical and molecular genetics of the phosphodiesterases (PDEs).

Authors:  Monalisa F Azevedo; Fabio R Faucz; Eirini Bimpaki; Anelia Horvath; Isaac Levy; Rodrigo B de Alexandre; Faiyaz Ahmad; Vincent Manganiello; Constantine A Stratakis
Journal:  Endocr Rev       Date:  2013-12-05       Impact factor: 19.871

4.  Immunohistochemical localisation of PDE5 in Leydig and myoid cells of prepuberal and adult rat testis.

Authors:  Angela Scipioni; Stefania Stefanini; Rocco Santone; Mauro Giorgi
Journal:  Histochem Cell Biol       Date:  2005-11-03       Impact factor: 4.304

Review 5.  Pharmacological preconditioning with phosphodiestrase inhibitor: an answer to stem cell survival against ischemic injury through JAK/STAT signaling.

Authors:  Manju Yadav; Pooja Kumari; Varsha Yadav; Sanjay Kumar
Journal:  Heart Fail Rev       Date:  2020-03       Impact factor: 4.214

Review 6.  Therapeutic potential of PDE modulation in treating heart disease.

Authors:  Walter Knight; Chen Yan
Journal:  Future Med Chem       Date:  2013-09       Impact factor: 3.808

Review 7.  Phosphodiesterase-5 expression and function in the lower urinary tract: a critical review.

Authors:  Ching-Shwun Lin; Maarten Albersen; Zhongcheng Xin; Mikio Namiki; Dieter Muller; Tom F Lue
Journal:  Urology       Date:  2013-01-17       Impact factor: 2.649

8.  Expression, activity, and pro-hypertrophic effects of PDE5A in cardiac myocytes.

Authors:  Manling Zhang; Norimichi Koitabashi; Takahiro Nagayama; Ryan Rambaran; Ning Feng; Eiki Takimoto; Trisha Koenke; Brian O'Rourke; Hunter C Champion; Michael T Crow; David A Kass
Journal:  Cell Signal       Date:  2008-08-26       Impact factor: 4.315

Review 9.  Cardiac cyclic nucleotide phosphodiesterases: function, regulation, and therapeutic prospects.

Authors:  W E Knight; C Yan
Journal:  Horm Metab Res       Date:  2012-09-05       Impact factor: 2.936

10.  Effect of vardenafil on semen parameters in infertile men: a pilot study evaluating short-term treatment.

Authors:  R Rago; P Salacone; L Caponecchia; I Marcucci; C Fiori; A Sebastianelli
Journal:  J Endocrinol Invest       Date:  2012-04-18       Impact factor: 5.467

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.